The Potential Synergistic Effect f EGCG-S and Antibiotics on the ESKAPE Bacteria Group by Elsayed, Summer
Montclair State University
Montclair State University Digital Commons
Theses, Dissertations and Culminating Projects
5-2019
The Potential Synergistic Effect f EGCG-S and
Antibiotics on the ESKAPE Bacteria Group
Summer Elsayed
Follow this and additional works at: https://digitalcommons.montclair.edu/etd
Part of the Biology Commons
 1 
Abstract 
The primary etiology of nosocomial infections derives from the following 
pathogenic ESKAPE organisms: Enterococcus faecium/faecalis, Staphyloccoccus 
aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas 
aeruginosa and Enterobacter species. These opportunistic organisms are multidrug 
resistant and have the ability to form biofilm, which pose a great threat to clinical 
medicine. Evidence has shown catechins found in green tea (Camellia sinensis), 
have antibacterial activity. In this study, a modified polyphenolic catechin 
compound Epigallocatechin-3-gallate stearate (EGCG-S) was used to research its 
potential to inhibit ESKAPE growth and biofilm formation. In addition, synergistic 
ability of EGCG-S with antibiotics was also studied. Disk diffusion and colony 
forming unit assays were conducted to study the effects of EGCG-S, with and 
without antibiotics on the ESKAPE bacteria. Growth in the presence of EGCG-S 
was monitored and biofilm formation was analyzed. In all of the microorganisms, 
EGCG-S was able to enhance the antimicrobial activity of some antibiotics, 
converting them from resistant to sensitive or intermediate.  The results indicated 
that EGCG-S can inhibit the growth and biofilm formation of bacteria at both 250 
and 500 µg/ml.  
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Introduction 
 
Bacterial Resistance  
Microorganisms that previously did not pose a great threat to our global health are 
now causing severe diseases in humans and wildlife, due to the rise of multi drug resistant 
(MDR) organisms (Antibiotic 2017; Shin et al. 2018). The upsurge in MDR organisms is 
attributed to bacteria, virus and fungi is ability to quickly adapt/acquire resistance to 
medications (antifungals, antibiotics, and antivirals) (Antibiotic 2017; Shin et al. 2018). 
These microorganisms possess the physiological advantage of genetic plasticity, due to 
horizontal gene transfer, therefore, they can quickly adapt and evade present day 
medications (Antibiotic 2017; Shin et al. 2018). Thus, they outsmart the host’s immune 
system and use their hosts as a vector, which spreads MDR organisms communally (J.W 
Betts et al., 2011).  
The multifactorial causes of antibiotic resistance include inadequate diagnostic 
techniques, superfluous use of antibiotics and the use of antiseptics (Antibiotic 2017; Shin 
et al. 2018).  In health care settings, harsh chemicals are used readily to clean surfaces 
leaving behind antibiotic resistant pathogens that are easily spread through medical 
equipment and medical personal (Saccucci et al. 2018). Therefore, nosocomial infections 
have become more virulent and are easily transmitted to immunocompromised patients 
with long hospital stays (Saccucci et al. 2018).  These MDR organisms are opportunistic 
and do not normally impact healthy individuals, unless it is a severely virulent strain 
(Antolak et al. 2017; Saccucci et al. 2018) 
Additionally, another mode of transmission of MDR bacteria is through 
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consumption, grocery store products contain antibiotic resistant bacteria in various 
products (Antolak et al. 2017). Cheese, meat, fruit, canned food and vegetables all contain 
preservatives, which aim to inhibit microorganismal growth, however, some are ineffective 
and cause consumers severe infections (Antolak et al. 2017). 
Mechanisms of Bacterial Resistance 
Bacteria attain antibiotic resistance intrinsically or through acquired resistance 
(Alekshun & Levy, 2015). Intrinsic resistance is a species’ ability to evolve resistance 
against antimicrobial agents that are naturally found in their habitat (Munita et al., 2016). 
Efflux pumps are common intrinsic mechanisms that allow bacteria to eject and expel 
antibiotics, which will be discussed further below (Alekshun & Levy, 2015).   
 Acquired resistance is categorized by species who were once susceptible to antibiotics and 
are now resistant to those antibiotics (Munita et al., 2016). They are able to acquire 
resistance through horizontal gene transfer in the three ways:  transformation, transduction 
and conjugation (Rogers et al., 2018).  
Bacteria acquire antibiotic resistance genes via transformation from free DNA, 
transduction from viral DNA and conjugation through a plasmid (Alekshun & Levy, 2015). 
Transformation is when free DNA undergoes recombination, while an antibiotic resistance 
gene is inserted into the organisms’ chromosome (Alekshun & Levy, 2015).  Free DNA is 
commonly in integron form, containing genetic elements in cassettes.  Cassettes are 
captured genes that can be carried, expressed and integrated into a chromosome via 
recombination (Domingues et al. 2012).  Another example of mobile DNA that can 
transform a chromosome is a transposon (Alekshun & Levy, 2015). There are three 
common types of transposons: 1. complex contains genetic material for various proteins in 
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addition to antibiotic resistance genes, 2. composite which contain genes that encode 
transposition, and 3. Conjugative which is the ability to transfer resistance genes through 
cell to cell interaction (Alekshun & Levy, 2015; Rogers et al., 2018). Transduction is the 
process in which antibiotic resistance is acquired from foreign viral DNA (bacteriophage), 
through transposition (Alekshun & Levy, 2015; Rogers et al., 2018). Transposition is an 
alteration of gene order when a gene is inserted into the chromosome, commonly causing 
a mutation (Alekshun & Levy, 2015). Conjugation is when a plasmid replicates 
independently within an organism expressing resistance, although, plasmids can also 
contain transposable elements that can integrate into the chromosome via transposition and 
recombination (Alekshun & Levy, 2015).  
There are four common antibiotic resistance mechanisms that are acquired; Efflux 
pumps, blocked penetration, inactivation of enzymes and target modification shown in 
Diagram 1 (Tu, 2010). Efflux pumps allow bacteria to regulate the amount of antibiotics 
within the cell, decreasing the dose it is subjected to resulting in survival (Tu, 2010).   
Blocked penetration is when an organism has the ability to accumulate the antibiotics, but 
does not allow it to reach its cellular target (Tu, 2010).   Bacteria can gain a resistance gene 
that encodes for an enzyme that inactivates the antibiotic listed below (Tu, 2010). Target 
modification resistance is when a bacteria is able to alter the antibiotic binding site 
structurally and the antibiotic will not be able to bind (Tu, 2010).    
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Figure 1:  Mechanisms of bacterial resistance and the specific groups of antibiotics that 
are inactivated through  these mechanisms (Tu, 2010). 
ESKAPE organisms  
The ESKAPE group consists of the following bacterial species: Enterococcus faecium, 
Staphyloccoccus aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas 
aeruginosa and Enterobacter spp.. The ESKAPE group organisms are the leading cause 
of nosocomial infections. The ESKAPE organisms are on the World Health Organization 
(WHO) priority pathogens for research development (R&D) of new antibiotics (De 
Freitas, 2013; Santajit & Indrawattana, 2016). These multidrug resistant bacteria  pose a 
great threat to clinical medicine, due to their antibiotic resistant isolates, extremely 
virulent genetic strains, decreased antibiotic cell permeability and their ability to form 
biofilm (Santajit & Indrawattana, 2016). 
  
 14 
a.  Enterococcus faecium/faecalis 
Enterococcus faecium and faecalis, mostly endogenous opportunistic 
infections, are the only species out of 38 that make up the genera Enterococcus that 
are clinically pertinent  (Quiloan, Vu, & Carvalho, 2012; Santajit & Indrawattana, 
2016). These gram positive facultative anaerobes are found in pairs and chains and 
colonize the normal flora of the gastrointestinal tract in mammals  (Quiloan et al., 
2012; Santajit & Indrawattana, 2016).  
E. faecium is on the World Health Organization (WHO) priority pathogens 
list for research and development (R&D) of new antibiotics and is listed as a high 
priority pathogen (level 2) (De Freitas, 2013). E. faecium is highly resistant to 
vancomycin and is thought to be transmitted through humans during consumption 
of farm animals as they are a reservoir for Enterococcus faecalis and faecium 
(Aarestrup et al., 2000). Resistance genes are found on their conjugative plasmids 
and transposons (Aarestrup et al., 2000).  These organisms can cause various 
diseases including endocarditis, urinary tract infections, post-surgical infections 
and during wound healing, septicemia, meningitis and pelvic/intraabdominal 
infections (Quiloan et al., 2012).  
Various studies have concentrated on comparing E. faecium and E. faecalis 
antibiotic resistant strains (Aarestrup et al., 2000). A study published by the journal 
of Diagnostic Microbiology and Infectious Disease found that both isolates from 
human stool samples, pigs and chickens, specifically broilers (bred for 
consumption), contained analogous patterns of resistance and genes encoding for 
resistance; signifying resistance transmission among broilers, humans and pigs 
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(Aarestrup et al., 2000). The researchers in the aforementioned study tested for 
antibiotic resistance genes of twelve different antimicrobial agents utilizing 
forward and reverse primers to test the isolates for potential susceptibility or 
resistance (Aarestrup et al., 2000). The transmission of antibiotic resistant 
E.faecalis and E.faecium between chickens, humans and pigs was determined to be 
likely after utilizing the primers and analyzing the isolates from multiple samples 
(Aarestrup et al., 2000).   
Table 1: PCR primers used to probe for the antibiotic resistance genes for the following 
antibiotics:  bacitracin, chloramphenicol, gentamicin, kanamycin, penicillin, streptomycin, 
quinupristin/dalfopristin, tetracycline  and vancomycin. (Aarestrup et al., 2000).   
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b. Staphylococcus aureus 
Staphylococcus aureus is a gram-positive bacterium that is essential to 
mammalian normal flora, however, Methicillin resistant Staphylococcus aureus 
(MRSA) causes bacterial infections that are highly resistant to penicillin and 
contain carbapenem-resistance (Antibiotic 2017). MRSA causes severe flesh-
eating and soft tissue infections and it commonly infects patient’s joints post 
orthopedic surgery, therefore, causing complications and delaying the wound 
healing process (Bin et. al 2017). S. aureus is on the World Health Organization 
(WHO) priority pathogens list for research and development (R&D) of new 
antibiotics listed as a high priority pathogen (level 2) (De Freitas, 2013). 
S. aureus has increased its resistance to antibiotics by 45% from 1980 to 
2000 (Man et al., 2018). MRSA is readily communally acquired,  affecting athletes,  
those who live in close quarters  and patients in hospital settings and health care 
settings  (Klevens et al., 2007). These infections are often invasive and have a poor 
prognosis.  In 2005 there were 1598 deaths related to MRSA in the United States 
alone (Klevens et al., 2007).  
c. Acinetobacter baumannii  
Acinetobacter baumannii  is an organism commonly found in soil,  and is a 
rising nosocomial infection (Santajit & Indrawattana, 2016). This organism is a 
gram negative, coccobacillus that has been easily transmitted in war zones as it was 
prevalent in the Iraq war  (Howard, O’Donoghue, Feeney, & Sleator, 2012; Santajit 
& Indrawattana, 2016). Earning the nickname  “Iraqibacter”, as it infected 
numerous American soldiers (Howard, O’Donoghue, Feeney, & Sleator, 2012). 
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A. baumannii is on the World Health Organization (WHO) priority 
pathogens list for research  and development (R&D) of new antibiotics and is listed 
as priority one pathogen (critical priority) (De Freitas, 2013).  It infects the skin, 
soft tissue, upper respiratory tract and urinary tract (Howard et al., 2012; Santajit 
& Indrawattana, 2016). It is a true nosocomial infection that infects 
immunocompromised patients with prolonged hospital stays (Howard et al., 2012).  
A. baumannii is able to survive on hands for a long duration allowing it to be a 
cause of cross contamination in the hospital setting, which is most dangerous in 
intensive care units and surgical units (Santajit & Indrawattana, 2016). 
d. Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a gram negative and  rod shaped bacteria 
(Santajit & Indrawattana, 2016). It is a part of the gastrointestinal normal flora 
(Santajit & Indrawattana, 2016). Pseudomonas commonly infects patients that are 
immunocompromised causing severe pneumonia or septicemia; in healthy patients 
it is the cause of ear infections and eye infections (Santajit & Indrawattana, 2016). 
It is also one of the main contributors to post-surgical infections. P. aeruginosa is 
a World Health Organization (WHO) priority for research and development (R&D) 
of new antibiotics and is listed as a priority one (critical priority) pathogen (De 
Freitas, 2013).  
e.  Klebsiella pneumoniae  
Klebsiella pneumoniae is a gram-negative encapsulated rod-shaped bacteria 
that commonly causes pneumonia in patients with alcoholism and diabetes (Ashurst 
et al., 2019). K. pneumoniae is colonizer of the GI tract and nasopharynx (Ashurst 
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et al., 2019). K. pneumoniae is known to colonize the GI tract due to reoccurring 
antibiotic treatment, leaving behind antibiotic resistant K. pneumoniae (Ashurst et 
al., 2019). K. pneumoniae is a part of the family Enterobacteriaceae,  therefore, it 
is also on the WHO priority pathogens list for R&D of new antibiotics and is listed 
as a priority one (critical priority) pathogen (De Freitas, 2013; Santajit & 
Indrawattana, 2016 ). 
f. Enterobacter aerogenes 
Enterobacter aerogenes is also a gram-negative rod-shaped bacteria 
(Davin-Regali et al., 2015).  It readily impacts patients who are utilizing ventilators 
and is most commonly transmitted within the intensive care unit (Davin-Regali et 
al., 2015).    E. aerogenes is a part of the family Enterobacteriaceae,  therefore, it 
is also on the WHO priority pathogens list for R&D of new antibiotics and is listed 
as a priority one (critical priority) pathogen (Davin-Regali et al., 2015; De Freitas, 
2013; Santajit & Indrawattana, 2016 ). 
Introduction to Antibiotics and Alternative Treatment Options  
Antibiotics are commonly derived from fungi, actinomycetes or bacteriotoxins.  
They work by either halting growth/proliferation within the host or by causing bacterial 
apoptosis (Saccucci et al. 2018). These drugs can target different parts of the microbial life 
cycle in various ways, such as disrupting the bacteria’s transcriptional (DNA synthesis) 
and translational material (RNA synthesis), as well as disrupting: bacterial enzymatic 
function, cell wall permeability and protein synthesis (Saccucci et al. 2018). Thus, bacterial 
growth and proliferation is inhibited.  
Antibiotics are prescribed to humans and animals (livestock). Animals farmed for 
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consumption are given antibiotics to gain weight as well as to assure they do not spread 
disease (Bischoff et al. 2016). However, they spread the resistance to those who eat 
antibiotic treated meat and produce (Bischoff et al. 2016). In South Africa, antibiotic 
medications are sold over the counter for personal use and for livestock. These antibiotic 
prescriptions are a free for all in many third world countries, which is a large contributing 
factor to the prevalence of MDR organisms (Van den Honert, et al. 2018). Replacing 
antibacterial treatment with emerging natural remedies may reduce the further spread of 
antimicrobial resistance (Bischoff et al. 2016). Evidence has shown that medicinal plants 
exhibit antibacterial properties in livestock. In Switzerland farmers utilize homemade 
chemical extracts of marigold flowers, stinging nettle, chamomile and coffee as 
antimicrobials for their livestock (Bischoff et al. 2016). These chemical extracts have been 
shown to be effective on gastrointestinal, metabolic and epidermal infections when tested 
by veterinarians in Europe (Bischoff et al. 2016).  
Natural Remedies and Previous Studies  
Due to the prevalence of antibiotic resistant microorganisms and lack of treatment 
options, there is a high demand to research alternative treatment options to circumvent 
antibiotic resistance. Researchers have discovered that essential oils were able to reverse 
effects of antibiotic resistance when administered in conjunction with antibiotics.   This in 
vitro study utilized antibacterial resistant bacteria from patients whom were unresponsive 
to antibiotic treatment (Lahmar et al. 2017).  
Additionally, isolated bacteriocins have been utilized to treat infections. 
Bacteriocins are natural anti-bacterial toxins released by bacteria, specifically lactic acid 
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bacteria (Bin et. al 2017). Recent evidence has shown that bacteriocins from Lactobacillus 
rhamnosus have the ability to halt antibiotic resistant Staphylococcus aureus induced knee 
implant infections in a rabbit model (Bin et. al 2017). Staphylococcus aureus form bacterial 
biofilms, as they contain highly adhesive proteins that make infections very difficult to 
treat.  Therefore, these bacteriocins have been shown to inhibit gram positive bacterial 
infections, as they are highly water soluble, which can be utilized in further studies (Bin 
et. al 2017). Additionally, evidence has shown that the natural oils, Pistacia lentiscus, 
Teucruim ramosissimum and Pituranthos chloranthus, coupled with antibiotic treatments 
are singularly effective in arresting bacterial growth of resistant bacteria (Lahmar et al. 
2017). Amoxicillin, when coupled with essential oils, was actually able to decrease 
MRSA’s resistance to the antibiotics (Lahmar et al. 2017). The essential oils T. 
ramosisimum, P. chloranthus and P. lentiscus are made up of chemicals that are thought to 
be antimicrobial due to their ability to inhibit bacteria, when coupled with antibiotics, and 
their ability to reverse antibiotic resistant nosocomial bacterial growth alone (Lahmar et al. 
2017). The antibacterial components they postulate are responsible for this antibacterial 
resistance reversal effect include: β-eudesmol, limonene, p-Cymene, 1,6- germacradien-5-
ol, α-pinene, cedreanol, β-caryophyllene and sabinene (Lahmar et al. 2017). These 
compounds may be promising components in future antibiotics; however, we do not know 
if microorganisms will be able to mutate and resist the synergistic effect of essential oils 
and antibiotics (Lahmar et al. 2017).  
Additionally, theaflavins, catechins, and epicatechins derived from black tea and 
green tea have been found to have antibacterial properties (Betts et al. 2011; De Oliveira 
et al. 2015). Stenotrophomonas maltophilia and Acinetobactor baumannii are hospital 
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acquired antibiotic resistance bacteria. Recent evidence has shown that polyphenols, 
theaflavins and epicatechin derived from black tea exhibit potential antibacterial properties 
against S. maltophilia and A. baumanni (Betts et al. 2011).  
Furthermore, ethanol extracts from plants have shown antibacterial properties. The 
plants include green tea leaves, cinnamon bark, licorice root and elderberry flowers 
(Antolak et al. 2017). Evidence has shown that the plants listed above that contain ethanol 
extracts with preservative-like properties can actually inhibit the preservative resistant, 
opportunistic, infectious agents Asia bogorensis and Asia lannensis, which are gram-
negative bacteria that contaminate soft drinks as well as other products (Antolak et al. 
2017). These bacteria are able to grow in anoxic environments and are resistant to present 
preservatives: potassium sorbate, sodium benzoate and dimethyl dicarbonate (Antolak et 
al. 2017). However, the elderberry extract was able to slow the growth of the A. lannensis 
and A. bogorensis bacteria and green tea leaves, cinnamon and licorice extracts showed a 
statistically significant ability to halt bacterial growth in the beverage in this study (Antolak 
et al. 2017). Therefore, these natural extracts may be able to be used in preservations, 
pushing us away from antibacterial use that continues to add to the epidemic of resistant 
microorganisms (Antolak et al. 2017).  
Alternative Treatment using Catechin EGCG-S from Camelia sinesis (Green Tea) 
Evidence has shown that catechins found in green tea (Camellia sinensis), including 
Epigallocatechin-3-gallate (EGCG), Epicatechin (EC), Epicatechin-3-Gallate (ECG) and 
Epigallocatechin (EGC) are all catechin flavonoids that are known for their anti-
inflammatory and antimicrobial  processes. Shown in Figure 2, EGCG contains a longer 
carbon chain and is more stable than the other catechins.  
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  Additionally, epigallocatechin-3-gallate stearate (EGCG-S), which is EGCG, 
esterified is shown in Figure 3.  EGCG interacts with bacterial transcription potentially 
increasing antibiotic permeability (Serra, Mika, Richter, & Hengge, 2016; Xiong et al., 
2017; Zaveri, 2006). However, EGCG is not stable; more stable lipophilic modification of 
EGCG derivatives were synthesized yielding the compound shown in Figure 5. EGCG-S 
is a more stable derivative in vitro and has been shown to inhibit bacteria secondary to 
inducing endogenous oxidative stress and decreasing biofilm formation (Xiong et al., 
2017;Paschalis et al., 2019).  In this study, we are studying the potential synergistic effect 
of epigallocatechin-3-gallate stearate in conjunction with antibiotics on the ESKAPE 
bacteria and E. faecalis.  
 
Figure 2: Molecular Structure of EC, ECG, EGC and EGCG (Laishun et al, 1997). 
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Figure 3: Esterification of EGCG-S (Ali et al., 2012) 
 
 
Figure 4: Molecular Structure of EGCG-S (Ali et al., 2012) 
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Objectives of Study 
The research objectives are as follows: 
1. Determine the Minimum Inhibitory Concentration (MIC) of EGCG-S on the 
growth and viability of ESKAPE bacteria  
2. Determine the MIC of EGCG-S on the ESKAPE pathogens’ biofilm 
3. Study the potential synergistic effect of EGCG-S with selected antibiotics  
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Materials and Methods 
 
Experimental Set Up Standard Procedure 
The Biosafety Level 2 (BSL-2) hood was wiped down with 10% bleach and 
exposed to ultraviolet light for 20 minutes before and after experiment. 
 
Media Preparation 
Seven types of media were used in this study:  Brain Heart Infusion Agar (BHI-A), 
Brain Heart Infusion Broth (BHI-B), Mueller Hinton Agar (MHA), Nutrient Agar (NA), 
Nutrient Broth (NB), Tryptic Soy Agar (TSA) and Tryptic Soy Broth (TSB). Each medium 
was prepared according to manufacturer’s protocol and autoclaved accordingly. Each 
individual agar medium was poured into plates and left in sterile hood overnight to solidify. 
The following day the solidified agar plates were packaged in a plastic sleeve, taped, 
labeled and stored at 4˚C.  
Organism Optimal Medium 
Enterococcus faecium (E. faecium) BHI-A & BHI-B 
Enterococcus faecalis (E. faecalis) NA & NB 
Staphylococcus aureus (S. aureus) NA & NB 
Klebsiella pneumoniae (K.pneumoniae) NA & NB 
Pseudomonas aeruginosa (P.aeruginosa) NA & NB 
Acinetobacter baumannii (A. baumanniii)  TSA & TSB  
Enterobacter aerogenes (E. aerogenes) NA & NB 
Table 2: The optimal media to maintain and grow each bacterium  
a. Brain Heart Infusion Agar:  
BHI-A from Criterion Dehydrated Culture Media was prepared combining 
49.7gm of BHI-A medium with 1L of deionized water. The medium was 
autoclaved for 15 minutes at 121˚C. Then BHI-A medium was poured into 
mono plates in order to assure optimal growth of E. faecium, which was 
inoculated using aseptic techniques and continuous streak method every two 
weeks to maintain pure culture.  
b. Brain Heart Infusion Broth:  
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BHI-B from Criterion Dehydrated Culture Media was prepared combining 
37.0gm of BHI-B medium with one liter of deionized water. The medium was 
autoclaved for 15 minutes at 121˚C. Ten milliliters (10 mL) of BHI-B medium 
were then aliquoted into multiple test tubes to be used for further experiments.  
c. Mueller Hinton Agar:  
MHA from Carolina Biological Supply was prepared by weighing out 38gm of 
the medium in 1L of deionized water. The medium was autoclaved for 15 
minutes at 121˚C. The MHA medium was poured into mono plates to be used 
for Kirby-Bauer Disk Diffusion.  
d. Nutrient Agar:  
NA from Criterion Dehydrated Culture Media combining 20.5 gm of medium 
in 1L of deionized water. The medium was autoclaved for 15 minutes at 121˚C. 
After retrieval from the autoclave, of NA was poured into mono plates in order 
to assure optimal growth of E. faecalis, S. aureus, E. aerogenes, K. pneumoniae, 
and P. aeruginosa, which were inoculated using aseptic techniques and 
continuous streak method every two weeks to maintain pure culture. 
Additionally, NA was used during the Rapid Agar Plate Assay (RAPA).  
e. Nutrient Broth:  
NB from Ward’s Science was prepared combining 8 gm of medium in 1L of 
deionized water. The medium was autoclaved for 15 minutes at 121˚C. After 
retrieval from the autoclave, 5 mL of NB were aliquoted into multiple test tubes 
in preparation for overnight cultures of E. faecalis, S. aureus, E. aerogenes, K. 
pneumoniae, and P. aeruginosa.  
f. Tryptic Soy Agar Preparation 
TSA from Carolina Biological Supply was prepared using 30 grams of TSA 
powder media and 1L of deionized water. The medium was autoclaved for 15 
minutes at 121˚C. The TSA medium was poured into mono plates to assure 
optimal growth of A. baumannii, which was inoculated using aseptic techniques 
and continuous streak method every two weeks to maintain pure culture.  
e. Tryptic Soy Broth Preparation 
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TSB from Carolina Biological Supply was prepared using 30 gm of TSB media 
and 1L of deionized water. The medium was autoclaved for 15 minutes at 
121˚C. After retrieval from the autoclave, 5 mLs of TSB medium were 
aliquoted into multiple test tubes for further use.  
 
Bacteria utilized and maintained throughout this study   
a. Gram-positive bacteria used in this research:  
Enterococcus faecium (E. faecium), Enterococcus faecalis (E. faecalis), and 
Staphylococcus aureus (S. aureus).   
b. Gram-negative bacteria used in this research:  
Klebsiella pneumoniae (K. pneumoniae), Acinetobacter baumannii (A. 
baumannnii), Pseudomonas aeruginosa (P. aeruginosa) and Enterobacter 
aerogenes (E. aerogenes). 
  Utilizing a loop full of sterile stock culture every two weeks to maintain ESKAPE 
microorganisms in their corresponding agar medium shown in Table 2 via a continuous 
streak. Then placed in an incubator at 37˚C for 24 hours.  Each plate was wrapped in 
parafilm and stored at 4˚C for future use. Bacterial purity was checked periodically by 
using simple or Gram stain to confirm purity. In cases of contamination, a discontinuous 
steaking method was used to isolate colonies to start a new stock.  
 
Overnight Cultures 
One day prior to each experiment, overnight cultures were made utilizing sterile 
cultures from the continuous streaks that were maintained biweekly. Each bacterium was 
resuspended utilizing a sterile plastic loop from Argos Technologies in NB, TSB and BHI-
B according to each bacteria is optimal growth media shown in Table 2  above at 37˚C with 
continuously shaking at 250 rpm. 
 
Staining Techniques 
a. Simple Stain 
The protocol for simple stain used in this study is described in the Fifth Edition of 
Microbiology Laboratory Manual (Lee et al., 2018). Methylene blue was used for 
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simple stain to determine purity and morphology of all organisms in this study. 
Inoculations were retrieved from each bacterium is overnight culture.   
b. Gram Stain 
The Gram stain was used to differentiate between Gram-positive and Gram-
negative bacteria, as well as to determine the morphology of the bacteria. The Gram 
stain protocol was performed as described in the Fifth Edition of Microbiology 
Laboratory Manual (Lee et al., 2018). Each bacterium used was freshly prepared 
overnight culture.  
 
Polymerase Chain Reaction (PCR) to Amplify DNA for Sequence Analysis  
The purity of each culture was determined utilizing the following molecular 
mechanisms.  The procedure mirrored the Fifth Edition of Microbiology Laboratory 
Manual (Lee et al., 2018).  Sterile techniques were used throughout entire procedure. 
a. DNA extraction procedure described as follows:  
i. First a heat block was set to 100 ˚C and an ice bath was made.  
ii. For each sample 5% Chelex was vortexed for 60 seconds then 100 uL was 
aliquoted in six 1.5 mL labeled microcentrifuge tube.  
iii. Then 500 uL of each bacterium’s overnight culture was placed into the 
respective 1.5 mL microcentrifuge tube with the Chelex. Then each tube 
was vortexed for 30 seconds.  
iv. The six microcentrifuge tubes were placed on the heating block for ten 
minutes and then immediately placed on the ice bath for one minute.  
v. Samples were retrieved the samples from the ice bath  
vi. Each tube was vortexed for 30 seconds prior to being placed in the 
microcentrifuge for one minute at maximum speed (13,000 rpm/17,000g)  
vii. The supernatant containing the DNA extraction of each individual bacteria 
was then carefully pipetted into a newly labeled 1.5 mL microcentrifuge 
tube and kept on the ice bath.  
b. Determining the concentration and purity of each sample using 
NanoDropâ Readings:  
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i. The NanoDrop ND-1000 was blanked with 1.5 μL of sterile deionized water 
before and after each sample was tested.  
ii. 1.5 μL of each sample was pipetted onto the ND-1000 pedestal using a P-
10 micropipette. DNA concentration and purity was recorded in ng/μL and 
using A260/280 ratio, respectively.  
c. PCR preparation:  
i. The following materials were utilized to for 16S amplification: Forward 
primer 27F (5’- AGA GTT TGA TCC TGG CTC AG-3’) and reverse 
primer 1492R (5’- ACG GCT ACC TTG TTA CGA CTT-3’)  
ii. 20 μL of 2X Taq DNA Polymerase Master Mix (DNA Taq polymerase, 
dNTPs, sterile deionized water, buffer and MgCl2)  
iii. 2 μL of 10 μM 27F forward primer  
iv. 2 μL of 10 μM 1492R reverse primer  
v. 14 μL of nuclease-free water  
vi. 2 μL of microbial DNA  
vii. The six samples were placed on ice until placed in the thermal cycler.  
d. Thermal Cycler Program:  
i. The thermal cycler program utilized is as follows: 1.  95 ˚C for one minute 
in order to denature the double stranded DNA. 2. 25 cycles of the following:  
95 ˚C (10 seconds), 55 ˚C (10 seconds), and 72 ˚C (10 seconds). 3. 72 ˚C 
for 10 minutes to ensure to resynthesize the DNA molecules.  
ii. PCR products were stored in -20 ˚C refrigerator.  
e. Agarose Gel & Gel Electrophoresis  
i. 0.4gms of agarose powder was combined with 40 mL of electrophoresis 
buffer and then placed into microwave until powder was fully dissolved. 
Once heated 4 μL of SYBR SAFE was added utilizing a P10 micropipette.  
ii. Comb was placed into the gel box, followed by the liquid agarose gel.  
iii. Once the gel solidified, 10 μL from each individual PCR product from 
step 4.c. was placed into a six new microcentrifuge tubes and 2 μL of 
Bromophenol Blue dye was added to each tube.  
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iv. 12 μL of each sample was loaded into its own individual well. The first and 
last were loaded with12 μL of the DNA ladder.  
 
Preparation of Green Tea Polyphenols: 
Green Tea Polyphenol EGCG-S (U.S. Patent #: 20120171423) was purchased from 
Camellix LLC, Augusta, GA. EGCG-S stocks were prepared in concentrations of 10x of 
250μg/ml and 10x of 500μg/ml. 
 
Kirby-Bauer Disk Diffusion:  
 An overnight culture of each of the organisms (ESKAPE) was prepared. Individual 
loops were utilized to swab each of the seven organisms’ sterile culture and then plated to 
form a continuous streak on MHA plates for each bacterium. This protocol was 
completed twice for each trial. Trial one antibiotics were used only as treatment. Trial 
two antibiotics were used in conjunction with 25 μL of EGCG-S (250 μg/mL).  Three 
replicates were completed for each trial.  
  Seven of the plates were stamped with the following antibiotic disks: Bacitracin 
(B10), Chloramphenicol (C30), Erythromycin (E15), Polymyxin B (PB300), Tetracycline 
(TE30), and Vancomycin (VA30).  
The seven remaining plates were stamped with the same antibiotics and 25 μL of 
EGCG-S (250 μg/mL) was infused onto the filter disk at room temperature.  
The plates were placed into the incubator at 37 ˚C for 48 hours. The zone of 
inhibition (ZOI) was measured in millimeters (mm) after 24 and 48 hours respectively. 
Percentage of inhibition to test the potential synergistic effect of antibiotics and EGCG-S 
was calculated using the following formula.  
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Antibiotic Disk 
Potency 
Abbreviation Resistant  
(R) (mm) 
Intermediate  
(I) (mm) 
Susceptible 
(S) (mm) 
Bacitracin  10 μg B10 < 9 9 – 12  > 12 
Chloramphenicol 30 μg C30 < 13 13 – 17  > 17  
Erythromycin 15 μg E15 < 14 14 – 17  > 17  
Polymyxin 300 μg PB300 < 9  9 -11  > 11 
Tetracycline  30 μg TE30 < 15  15 – 18  >18 
Vancomycin  30 μg VA30 < 9 20-22 >12 
Table 3: Kirby Bauer Disk Diffusion Categories  = 𝐴 − 𝐵𝐵 	× 	100	𝐴 = 𝑍𝑂𝐼	𝑜𝑓	𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑	𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐵 = 𝑍𝑂𝐼	𝑜𝑓	𝑅𝑒𝑠𝑝𝑒𝑐𝑡𝑖𝑣𝑒	𝐴𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐	𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
Equation 1: % of ZOI increase/ decrease  
 
Growth Curve of Microorganisms:  Standard Growth Curve of the ESKAPE 
organisms and The Effect of EGCG-S on Growth of ESKAPE Microorganisms  
Overnight cultures were prepared and diluted using the specific broth for each 
bacterium with an Optimal Density (OD) of 0.1 at 600nm. A 48 well plate was used to 
prepare the seven microorganisms and was placed in a shaking incubator at 125 rpm at 
optimal temperature. Multi-plate reader, TECAN InfiniteM200 Pro, was used to monitor 
the growth at 600nm every hour for 10 hours with a final reading taken at 24 hours. The set 
up for this study is shown in Table 4. The control contained 450 μL of the diluted overnight 
culture and 50 μL of its respective media to determine the standard growth curve for each 
microorganism shown in Table 2. Two treatment concentrations were utilized to study the 
effects of EGCG-S on bacterial growth and proliferation: 250 μg/mL (T1) and 500ug/ml 
(T2) shown in Table 4. The growth curve was plotted using the mean of duplicates with 
the Standard Deviation (SD) and plotted with OD (y-axis) vs. Time (x-axis). The 
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generation time was calculated for each bacterium during the exponential growth phase 
(three to five hours for each bacteria).  The equation used of determine generation time is: 
g = (log10 N1 – log10N0) / log102.to determine the doubling time required for each organism 
in different conditions.  
450 μL of E. 
faecium + 
50 μL of 
BHI-B 
(Control)  
450 μL of E. 
faecium + 
50 μL of 
250 μg/mL 
EGCG-S   
450 μL of 
E.faecium + 
50 μL of 500 
μg/mL 
EGCG-S   
450 μL of 
A.baumannii 
+ 50 μL of 
NB 
(Control) 
450 μL of 
A.baumannii 
+ 50 μL of 
250 μg/mL 
EGCG-S   
450 μL of 
A.baumannii 
+ 50 μL of 
500 μg/mL 
EGCG-S   
450 μL of E. 
faecalis  + 50 μL 
of NB(Control) 
Same as to 
the left.  
Same as 
above 
Same as 
above 
 Same as 
above 
Same as 
above 
Same as 
above 
Same as 
above 
450 μL of E. 
faecalis + 50 μL 
of 250 μg/mL 
EGCG-S   
Same as to 
the left  
450 μL of S. 
Aureus + 50 
ul of  NB 
(Control) 
450 μL of S. 
Aureus + 50 
μL of 250 
μg/mL 
EGCG-S   
450 μL of S. 
Aureus + 50 
μL of 500 
μg/mL 
EGCG-S   
450 ul of P. 
aeruginosa + 
50 μL μg/mL 
of NB 
(Control) 
450 μL of P. 
aeruginosa + 
50 μL of 250 
μg/mL 
EGCG-S   
450 μL of P. 
aeruginosa + 
50 μL of 500 
μg/mL 
EGCG-S   
450 μL of E. 
faecalis + 50 μL 
of 500 μg/mL 
EGCG-S   
Same as to 
the left  
Same as 
above 
Same as 
above 
Same as 
above 
Same as 
above 
Same as 
above 
Same as 
above 
TSB NA 
450 ul of K. 
pneumoniae 
+ 50 μL of 
NB 
(Control) 
450 ul of K. 
pneumoniae 
+ 50 μL of  
250 μg/mL 
EGCG-S   
450 ul of K. 
pneumoniae 
+ 50 μL of 
500 μg/mL 
EGCG-S   
450 ul of E. 
aerogenes + 
50 μL of NB 
(Control) 
450 ul of E. 
aerogenes + 
50 μL of 250 
μg/mL 
EGCG-S   
450 ul of E. 
aerogenes + 
50 μL of 500 
μg/mL 
EGCG-S   
TSB + 
Treatment 1  
NA + 
Treatment 
1 
Same as 
above  
Same as 
above  
Same as 
above 
Same as 
above 
Same as 
above 
Same as 
above 
TSB + 
Treatment 2 
NA + 
Treatment 
2 
Table 4: 48 well plate set up: the control contained 450 ul of the diluted overnight 
culture and 50 ul of its respective media this was the control (standard growth curve) for 
each microorganism. Two treatment concentrations were utilized to study the effects of 
EGCG-S on bacterial growth and proliferation: 250 µg /mL (T1) and 500 µg /ml (T2) 
shown above.   
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Effect of Green Tea Polyphenol EGCG-S on Biofilm 
Two 48 well plates were set up identically to Table 4 (growth curve table) and then 
placed in the incubator for 72 hours at 37 ˚C. Each micropipette tip used during this 
procedure was discarded after each reagent was placed into a single well. After 72 hours, 
the plates were retrieved from the incubator and the following two methods were used to 
quantitatively study the biofilm formation: 
a. Crystal Violet Assay  
i. Each well was aspirated and then washed with 250 μL of 1 x Phosphate 
Buffered Saline (PBS) three times.  
ii. Crystal Violet (0.1%) was added into each well and allowed to sit for 30 
minutes. After 30 minutes, the dye was aspirated.  
iii. Each plate was inverted and incubated overnight on sterile absorbent pad at 
room temperature (25 ˚C) for 24 hours.  
iv. The wells were allowed to air dry for 24 hours. Each wall was cleaned 
utilizing PBS, 30% acetic acid and sterile cotton swabs.  
v. Then 500 μL of 30 % acetic acid was placed into each well.  
vi. The Multi-plate reader, TECAN InfiniteM200 Pro, was used to measure the 
biofilm formation at the OD of 595nm.  
b. Resazurin Assay  
i. Each well was aspirated and then washed with 250 μL of 1 x Phosphate 
Buffered Saline (PBS) three times.  
ii. Then 200 μM of Resazurin working solution (original stock is 2mM, 5 mg 
of Resazurin powder + 10 mL of PBS) was added to each well.  
iii. The 48 well plate was then covered with aluminum foil and placed in the 
freezer to incubate at 4 ˚C for 24 hours.  
iv. The Multi-plate reader, TECAN InfiniteM200 Pro, was then used to 
measure fluorescence with an excitation wavelength of 560nm and 
emission wavelength at 590nm.  
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Pre and Post Application of EGCG-S Using Rapid Agar Plate Assay (RAPA) 
a. Pre-Application of EGCG-S 
Seven specific agar plates for each of the ESKAPE organisms as seen in 
Table 2 were utilized.  Then 100 μL of 250 μg/mL of EGCG-S was then applied to 
each plate and left to sit for one hour.  
All microorganisms were diluted to an OD600nm reading of 0.10 and diluted 
to 10-6 and 10-8 using sterile DI H2O. The dilution factor varied among species. The 
dilution factor for all samples was optimized to determine CFUs in a countable 
range. Then 100 μL of each bacteria from the optimal dilution factor was then added 
to its corresponding labeled and treated agar plate. Samples were spread throughout 
the entirety of the agar and then placed in the incubator at 37 ˚C for 24 hours. The 
CFUs were counted after the 24 hour incubation period and percent (%) of 
inhibition was calculated. 
b. Post-Application of EGCG-S 
First 100 μl of each of the ESKAPE organism dilutions from 11a. were 
plated on their respective agar plates as seen in Table 2 and allowed to air dry for 
five minutes. Then 100 μL of 250μg/mL of EGCG-S was obtained utilizing a P1000 
micropipette and applied onto the agar plates. EGCG-S was spread onto the entire 
plate utilizing a sterile plastic loop. Placed were placed into the incubator at 37 ˚C 
for 24 hours. The CFUs were counted after the 24 hour incubation period and % of 
inhibition was calculated. %	𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = (𝐶𝐹𝑈	𝑜𝑓	𝐶𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐶𝐹𝑈	𝑜𝑓	𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)𝐶𝐹𝑈	𝑜𝑓	𝐶𝑜𝑛𝑡𝑟𝑜𝑙 	× 	100% 
Equation 2: CFUs were counted for methods 11a-c the following day. Percent inhibition 
was calculated utilizing the formula above. 
 
Fluorescence Microscopy using BacLight™ Live and Dead Assay 
A sterile loop full of each individual ESKAPE bacteria was retrieved from the 
EGCG-S solution post application trial and smeared onto its corresponding labeled slide 
(ie. Kp Post-Treatment). A control for each bacterial sample was smeared onto a glass slide 
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corresponding to the bacteria. Fourteen slides in total were prepared in a dark room: seven 
were controls and seven of the bacteria that were treated with the post application of 
EGCG-S. Ten μL of Syto®9 dye from the LIVE/DEAD® BaclightTM Kit was added to 
each slide with a cover slip placed on top. Slide tray was covered with aluminum foil and 
left at room temperature for 10 minutes. Each slide was viewed under 400X total 
magnification using a ZEISS fluorescence microscope. 
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Results and Discussion 
In this study, seven microorganisms were used:  Gram-positive Bacteria: 
Enterococcus faecium/faecalis (E. faecium/faecalis), Staphyloccoccus aureus (S.aureus); 
Gram-negative  Bacteria: Acinetobacter baumanni (A. baumanni), Pseudomonas 
aeruginosa (P. aeruginosa), Klebsiella pneumoniae (K. pneumoniae) and  Enterobacter 
aerogenes (E. aerogenes).  To determine if antibiotics and EGCG-S worked 
synergistically, the following experiments have been performed.  
 
Determination of bacterial purity: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5a-5g:  Gram Stain of The ESKAPE Bacteria and E. faecalis  
a. E. faecium:  
i. In Figure 5a, the Gram Stain of E. faecium shows that it is a coccus 
(round) shaped bacteria that is found in pairs and clusters. The 
purple stained cells indicate that E. faecium is a gram-positive 
bacterium.  
b. E. faecalis:  
i. In Figure 5b: The Gram Stain of E. faecium is a cocci (round) shaped 
bacteria that is found in pairs and clusters. The purple stained cells 
5a. E. faecium 5b. E. faecalis 5c. S. aureus 
5d.  K. pneumoniae 5e.  A. baumannii 5f.  P. aeruginosa 5g. E. aerogenes 
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indicate that E. faecium is a gram-positive bacterium and no 
contaminants are present.  
c. S. aureus: 
i. In Figure 5c: The Gram Stain of S. aureus is cocci (round) shaped 
bacteria that is found in grape like structure, the purple stained cells 
indicate that S. aureus is a gram-positive bacterium as it is stained 
purple.  
d. K. pneumoniae:  
i. In Figure 5d: The Gram Stain shows K. pneumoniae, a  
bacillus (rod) shaped bacterium that contains a capsule surrounding it 
(encapsulated). The cells are stained pink, indicating it is a gram-
negative bacterium.  
e. A. baumannii:  
i. In Figure 5e: The Gram Stain shows that A. baumannii is a 
coccobacillus that did not retain the purple Gram stain dye.  
Indicating it is a gram-negative bacterium.  
f. P. aeruginosa: 
i. In Figure 5f: The Gram Stain shows that P. aeruginosa is a rod-shaped 
bacterium.  The cells are stained pink indicating it is a gram-negative 
bacterium as its thick peptidoglycan wall will not retain the dye.  
g. E. aerogenes: 
i. In Figure 6g: The Gram Stain shows that E. aerogenes is a rod-
shaped encapsulated bacterium. The cells are stained pink, 
indicating that it is a gram-negative bacterium.  
Each bacterium was homogeneous as determined by the Gram Stain. Thus, we can 
determine that our stock cultures are pure and no contaminants were present.  
 
DNA extraction and NanoDropÒ Readings: 
DNA extracted from E. faecium, E. faecalis, S. aureus, K. pneumoniae, A. 
baumannii, and E. aerogenes were analyzed. To assure that enough DNA was extracted 
 38 
for PCR, DNA concentration was measured. Additionally, purity was determined utilizing 
the NanoDrop absorbance ratio of 260nm over 280nm; a ratio that is close to 1.80 is 
considered pure (In et al., 2007).   
Organism  DNA concentration (ng/uL) A260/280 Ratio  
E. faecium 295.7 1.78 
E. faecalis 289.9 1.78 
S. aureus 292.1 1.74  
K. pneumoniae 323.8 1.67 
A. baumannii 1327.1 1.37 
P. aeruginosa 343.9 1.76 
E. aerogenes  279.6  1.74 
Table 5:  DNA concentration is measured in ng/uL. DNA purity was analyzed utilizing 
the absorbance ratio of 260nm over 280nm.  
 
The DNA concentrations for all of the bacteria tested ranged from 279.6 ng/uL – 
1327.1 ng/uL seen in Table 5. The purest DNA according to A260/280 ratios were 
extracted from E. faecium and faecalis both containing  a ratio of 1.78 followed by E. 
aerogenes, S. aureus, K. pneumoniae,  A. baumanni and E. aerogenes with 1.74, 1.74, 1.67, 
and 1.37 respectively. 
 
Gel Electrophoresis: 
PCR products were analyzed utilizing gel electrophoresis to ensure 16s rRNA gene 
amplification was present prior to DNA sequencing. The 16s rRNA gene band appeared in 
all of the organisms tested:  E. faecium, E. faecalis, S. aureus, K. pneumoniae, A. 
baumannii, and E. aerogenes shown in Figure 6. The DNA samples  were successfully 
amplified with 16s primers.  A. baumannii, E. faecium and S.aureus contained faint bands 
going from light to dark, respectively. E.aerogenes, E. faecalis and K. pneumoniae bands 
were bright. DNA concentration of A. baumanni was high with a reading of, 1327.1 ng/uL, 
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however, it contained the faintest band on the gel.  Since the band is visible, further DNA 
sequencing was carried out. P. aeruginosa is not shown. 
 
 
 
 
 
 
 
Table 6: Gel Electrophoresis Key: 
Showing which well corresponds with 
each bacterial PCR product or DNA 
ladder. The HiLo DNA ladder used to 
identify the 16s rRNA gene.  
 
Figure 6: Gel Electrophoresis of PCR products of A. baumannii, E. aerogenes, E. faecalis 
E. faecium, K. pneumoniae, S. aureus and a HiLo DNA marker on the left and right for 
reference. 
DNA sequencing:  
DNA sequencing was completed for all of the bacteria in this study E. faecium, E. 
faecalis, S. aureus, A. baumanni, P. aeruginosa, K. pneumoniae and E. aerogenes. The 
forward sequences were analyzed utilizing the Basic Local Alignment Search Tool 
(BLAST) for each of the bacterium to determine if their sequences matched their species 
on the BLAST database. E values that are closest to zero or less than zero indicate that it 
is a significant match. Red indicates the highest alignment scores shown on the right 
Figures 7a-7g.  
 
 
 
HL  HiLo DNA Marker  
Ab A. baumannii 
Ea  E. aerogenes 
Ef E. faecalis 
Efm  E. faecium 
Kp  K. pneumoniae 
Sa  S. aureus 
HL  HiLo DNA Marker  
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Figure 7a: BLAST Query for E.faecium  
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Figure 7b: BLAST Query for E. faecalis  
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Figure 7c: BLAST Query for S. aureus  
 
 
 
 43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7d: BLAST Query for A.baumannii  
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Figure 7e: BLAST Query for P. aeruginosa 
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Figure 7f: BLAST Query for K. pneumoniae.  
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Figure 7g: BLAST Query for E. aerogenes. 
 
The results confirmed the purity of the bacterial stocks. E. faecalis, S. aureus, K. 
pneumoniae, A. baumannii, P. aeruginosa and E. aerogenes all have E values of 0, 
therefore our stock cultures DNA sequences significantly matched with their species on 
BLAST. With percent identify of 89.10%, 100%, 95.72%, 97.50%, 97.51% and 93.08%, 
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respectively. E. faecium had an E value of 6e-123 and 81.85% identity, which is less 
significant, however, we can still determine that our culture is mainly pure.  
 
Kirby Bauer Disk Diffusion Test to Profile the Effect of Different Antibiotics and 
EGCG-S on ESKAPE 
The Kirby-Bauer disk diffusion test was used to determine the susceptibility of each 
bacteria to antibiotics alone and to compare the potential synergistic effect of EGCG-S and 
antibiotics. The zone of inhibition (ZOI) diameter was measured over the antibiotic disk in 
millimeters (mm) to measure the effectivity or susceptibility of each treatment.  The results 
are shown in Figures 8a-8g after 24 hours of incubation. The results are shown in Figures 
9a-9g after 48 hours of incubation. 
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 Resistant (R)   Intermediate (I)  Sensitive (S) 
Figures 8a-g: Each of the ESKAPE organisms were treated with six different antibiotics 
in one trial (left bar above each antibiotic category).  The second trial (right bar above each 
antibiotic category) utilized the same six antibiotics in combination with 25 µL of 250 
µg/mL EGCG-S. This study was repeated three times and the bar graphs contain a mean 
of the triplicate and SD after 24 hours. 
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9a.  9b. 
9c. 9d. 
9e.  9f. 
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 Resistant (R)   Intermediate (I)  Sensitive (S) 
 
Figures 9a-9g: Each bacteria was treated with six different antibiotics in one trial (left bar 
above each antibiotic category).  The second trial (right bar above each antibiotic category) 
utilized the same six antibiotics in combination with 25 µl of 250 µg/ml EGCG-S.  
 
The results indicate that EGCG-S can increase the ZOI of some antibiotics as shown 
in Tables 7-13, thus, increasing the efficacy of the following antibiotics shown in yellow 
and green in Tables 7-13.  
 
Enterococcus faecium (E. faecium) 
 
Antibiotics % ZOI Increase/Decrease Susceptibility Change 
Bacitracin (B10) 4.54% S à S 
Chloramphenicol (C30) 15.78 % S à S 
Erythromycin (E15) 9.52 % I à S 
Polymyxin B (PB300) 150 R à S 
Tetracycline (TE30) 7.69% S à  S 
Vancomycin (VA30) 5.26% S à S 
Table 7:  The numerical values of the percentage of synergy and status of susceptibility 
comparing trial one (solely antibiotics) and trial two (antibiotics in combination with 
EGCG-S) on E. faecium.  
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Enterococcus faecalis (E. faecalis) 
 
Antibiotics % ZOI Increase/Decrease Susceptibility Change 
Bacitracin (B10) 0 % S à S 
Chloramphenicol (C30) 7.14 % S à S 
Erythromycin (E15) 20.62 %  I à S 
Polymyxin B (PB300) 150 % R à S 
Tetracycline (TE30) -5.46 % S à S 
Vancomycin (VA30) -2.63 % S à S 
Table 8: The percentage of synergy and status of susceptibility comparing trial one 
(solely antibiotics) and trial two (antibiotics in combination with EGCG-S) after 48 hour 
treatment on E. faecalis.  
 
Staphylococcus aureus (S. aureus) 
 
Antibiotics % ZOI Increase/Decrease Susceptibility Change 
Bacitracin (B10) 18.18 R à  R 
Chloramphenicol (C30) 15.00% R à  R 
Erythromycin (E15) 10.00% I à I 
Polymyxin B (PB300) 27.27% I à S 
Tetracycline (TE30) -6.89% S à S 
Vancomycin (VA30) 0 S à  S 
Table 9:  The percentage of synergy and status of susceptibility comparing trial one 
(solely antibiotics) and trial two (antibiotics in combination with EGCG-S) after 48 hour 
treatment on S. aureus. 
 
Klebsiella pneumoniae (K.pneumoniae) 
 
Antibiotics % ZOI Increase/Decrease Susceptibility Change 
Bacitracin (B10) 86% R à S 
Chloramphenicol (C30) 6% R à I 
Erythromycin (E15) 44% I à R 
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Polymyxin B (PB300) 36% Sà S 
Tetracycline (TE30) -14% I à  S 
Vancomycin (VA30) 117% I à  S 
Table 10: The percentage of synergy and status of susceptibility comparing trial one 
(solely antibiotics) and trial two (antibiotics in combination with EGCG-S) after 48 hour 
treatment on K. pneumoniae. 
 
Acinetobacter baumannii (A. baumannii)  
 
Antibiotics  % ZOI Increase/Decrease Susceptibility Change  
Bacitracin (B10) 6.95 % Ià S 
Chloramphenicol (C30) 66.66 % R à  R 
Erythromycin (E15) 6.66 % I à  I 
Polymyxin B (PB300) 13.33% Ià S 
Tetracycline (TE30) 0 Sà S 
Vancomycin (VA30) 88.88 % Rà  I 
Table 11: The percentage of synergy and status of susceptibility comparing trial one 
(solely antibiotics)  and trial two (antibiotics in combination with EGCG-S) after 48 hour 
treatment on A. baumannii. 
 
Pseudomonas aeruginosa (P.aeruginosa) 
 
Antibiotics  % ZOI Increase/Decrease Susceptibility Change  
Bacitracin (B10) 0 % R à R 
Chloramphenicol (C30) 16.66 % R à  I 
Erythromycin (E15) 0 % I à  I 
Polymyxin B (PB300) 42.85 % I à S 
Tetracycline (TE30) 0 % S à  S 
Vancomycin (VA30) 0 % R à  R 
Table 12: The percentage of synergy and status of susceptibility comparing trial one 
(solely antibiotics)  and trial two (antibiotics in combination with EGCG-S) after 48 hour 
treatment on P.aeruginosa. 
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Table 13: The percentage of synergy and status of susceptibility comparing trial one 
(solely antibiotics) and trial two (antibiotics in combination with EGCG-S) after 48 hour 
treatment on E.aerogenes. 
 
Tables 7-13 are the percent of ZOI increase and status of susceptibility change 
comparing trial one and trial two after 48 hour treatment. In Tables 7 & 8 E. faecium and 
E. faecalis went from resistant to Polymyxin B to susceptible in combination with EGCG-
S, with 150% synergistic effect for both organisms. E. faecium and E. faecalis went from 
intermediate to susceptible to Erythromycin with 9.52% and 20.62% synergistic effect. S. 
aureus, A. baumannii, and P. aeruginosa went from intermediate to susceptible to 
Polymyxin B with a 27.27%, 13.33%, and 42.85% synergistic effect, respectively. A. 
baumannii went from intermediate to susceptible to bacitracin with a 6.95% synergy, and 
for vancomycin, the bacteria went from resistant to intermediate with a 88.88% synergy. 
P. aeruginosa went from resistant to intermediate susceptibility to chloramphenicol with a 
16.66% synergy.  
 
  
Enterobacter aerogenes (E. aerogenes) 
Antibiotics  % ZOI Increase/Decrease Susceptibility Change  
Bacitracin (B10) 183.3 % Rà S 
Chloramphenicol (C30) 0.00 % Rà I 
Erythromycin (E15) 88.88 % I à  R 
Polymyxin B (PB300) 155.5 % S à  S 
Tetracycline (TE30) 0 % I à S 
Vancomycin (VA30) 100% I à S 
 No change   Intermediate (I)  Sensitive (S) 
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The Effect of EGCG-S on Bacterial Growth 
 ESKAPE growth without treatment (control) and with EGCG-S at 500 µg/mL and 250 
µg/mL, respectively, was monitored for 10 hours in a 48 well plate with a final 24 hour 
reading. The absorbance was measured every hour at an OD 600nm. The results are shown 
in Figures10a - 10g.  
Bacterial standard growth curves contain a lag phase, exponential phase and a 
stationary phase. This was observed for all of the ESKAPE bacteria and E. faecalis . Once 
the nutrients in the media were depleted, the bacteria entered stationary phase. The 
exponential phase was seen in most of the bacteria between 1-5 hours, as seen in Figures 
10a-10g.  
 
Figure 10a: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of 
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of E. 
faecium at both µg/mL and 500 µg/mL 
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Figure 10b: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of 
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of E. 
faecalis at both 250 µg/mL and 500 µg/mL 
 
 
Figure 10c: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of 
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of S. aureus 
at both 250 µg/mL and 500 µg/mL 
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Figure 10d: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of 
EGCG-S (green).  EGCG-S was shown to inhibit the growth and proliferation of K. 
pneumoniae at both 250 µg/mL and 500 µg/mL 
 
 
Figure 10e: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of 
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of A. 
baumannii at both 250 µg/mL and 500 µg/mL.  
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Figure 10f: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of 
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of P. 
aeruginosa at both 250 µg/mL and 500 µg/mL.  
 
 
Figure 10g: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of 
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of E. 
aerogenes at both 250 µg/mL and 500 µg/mL.  
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Generation time was calculated in minutes based on the following equation: g = (log10 
N1 – log10N0) / log102.  If the generation time increases in the presence of EGCG-S, this 
indicates the polyphenol was able to slow growth and proliferation of the bacteria in 
comparison to their standard curve shown in blue in Figures10a-10g. The generation time 
was calculated utilizing Equation 2 and is in Table 14.  
The results indicated that EGCG-S potentially inhibited the growth at both 250 µg/mL 
and 500 µg/mL of all the ESKAPE bacteria. The 250 µg/mL concentration was more 
effective in inhibiting bacterial growth. EGCG-S was most effective in inhibiting S. aureus 
and E. aerogenes. 
 
Organism  Control  T1 (250 µg/mL) T2 (500 µg/mL) 
E. faecium 
 
112.2 (3-5 hours) 
 
-1219 (3-5 hours) 
 
-320.0 (3-5 hours) 
 
E. faecalis 
 
1025 (3-5 hours) 
 
-3621 (3-5 hours) 
 
-405.8 (3-5 hours) 
 
S. aureus 
 
263.0 (3-5 hours) 
 
-5189 (3-5 hours) 
 
635.7(3-5 hours) 
 
K. pneumoniae 
 
117.9 (1-3 hours) -697.4 (1-3 hours) -56.98 (1-3 hours) 
A. baumannii 
 
313.5 (3-5 hours) 
 
-1833 (3-5 hours) 
 
-151.9 (3-5 hours) 
 
P. aeruginosa 
 
238.3 (3-5 hours) 
 
10440 (3-5 hours) 
 
702.4 (3-5 hours) 
 
E. aerogenes 232.7 (3-5 hours) 
 
-1979 (3-5 hours) 
 
628.9 (3-5 hours) 
 
Table 14: Generation Time of ESKAPE after EGCG-S treatment 
 
The Effect of EGCG-S on Biofilm formation: Crystal Violet Assay and Resazurin 
Assay  
Biofilm formation was analyzed utilizing two methods: Crystal Violet and 
Resazurin assay. The results are shown in Figures 11 and 13.  E. faecalis showed a 
significant reduction in biofilm formation utilizing Resazurin Fluorescence shown clearly 
in Figures 13 and 14. Results were inconsistent, therefore, further studies are needed to 
optimize the methodology. 
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Figure 11: The effects of EGCG-S on biofilm formation utilizing the Crystal Violet 
Assay on E. faecium (Efm), E. faecalis (Ef), S. aureus (Sa), K. pneumoniae (Kp),  A. 
baumannii (Ab),  P. aeruginosa (Pa) and E. aerogenes (Ea). Two concentrations were 
tested (250 µg/mL and 500 µg/mL).  
 
 
Figure 12: EGCG-S percent inhibition of biofilm formation – Crystal Violet Assay 
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Figure 13: The effects of EGCG-S on biofilm formation utilizing the resazurin assay 
on E. faecium (Efm), E. faecalis (Ef), S. aureus (Sa), K. pneumoniae (Kp),  A. baumannii 
(Ab),  P. aeruginosa (Pa) and E. aerogenes (Ea). Two concentrations were tested (250 
µg/mL and 500 µg/mL).  
 
 
Figure 14: EGCG-S percent inhibition of biofilm formation – Resazurin Assay  
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Rapid Agar Plate Assay (RAPA): Colony Forming Units (CFU) Assay: 
EGCG-S was effective in inhibiting growth in both pre and post application on the 
bacteria as shown in Figure 15. Pre application percent inhibition ranged from 9.64%- 
61.71%. Post application was more effective in most cases as seen in Figure 15.   
Figure 15: Percent inhibition of CFU of E. faecium, E. faecalis, S. aureus and K. 
pneumoniae pre and post application of EGCG-S.  
 
Effect of EGCG-S on Microorganisms (Live vs. Dead Assay): 
bacterial samples treated with EGCG-S were viewed in comparison to controls 
utilizing the fluorescence scope. Figures 17a -17g, are the control bacteria under 
fluorescence which are fluorescing green, indicating that the cells are alive.  Figures 18a- 
18g are the treated bacteria under fluorescence which are mostly red, indicating that they 
are dead. The treated bacterial cells fluoresced red indicating that the treatment was 
effective, in comparison to the cells that fluoresced green from that were alive in the control 
(untreated).   
 
 62 
17a. E. faecium: Untreated
 
17b. E. faecium: Treated 
 
16b. E. faecalis: Untreated 
 
17b. E. faecalis: Treated
 
16c. S. aureus : Untreated 
 
17c. S. aureus : Treated 
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16d. K. pneumoniae: Untreated
 
17d. K. pneumoniae: Treated 
 
16e.A.baumannii: Untreated 
 
17e. A.baumannii: Treated
 
16f. P. aeruginosa: Untreated 
 
17f. P. aeruginosa: Treated 
 
16g: E. aerogenes: Untreated  17g: E. aerogenes: Treated  
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Figure 16a -16g:  RAPA post- application control bacteria under fluorescence, which are 
fluorescing green indicating that the cells are alive.  Figure 17a- 17g: RAPA post 
application treated bacteria under fluorescence. 
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Conclusion 
 All of the ESKAPE organisms utilized in this study were determined to be pure 
via cytological and molecular techniques. EGCG-S was shown to enhance the 
antimicrobial activity of various antibiotics, converting bacteria from resistant to 
intermediate or resistant to sensitive. The most effective outcome was converting E. 
faecalis from resistant to sensitive to Polymyxin B with a 150 % ZOI increase. The 
following table is a summary of the Disk Diffusion results and the potential synergy 
found in this study. Table 15 summarizes the antibiotics that worked the best in synergy 
with EGCG-S in increasing the diameter (mm) of the zone of inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 15: Summary of the most promising synergistic effect by organisms found in the 
study.  
The results indicated that EGCG-S potentially inhibited growth at both 250 and 
500 µg/ml when testing the effects of EGCG-S on the growth of bacteria, however, 250 
µg/ml was more effective in inhibiting bacterial growth and proliferation. The results of 
the effects of EGCG-S on biofilm formation were inconsistent, therefore future studies to 
optimize our methodology is required. Additionally, EGCG-S was able to kill the 
Organism Treatment (Antibiotics vs. 
EGCG-S in conjunction with 
antibiotics)  
E. faecalis:  
 
Erythromycin: Ià R 
Polymyxin B: Rà S 
E . faecium Erythromycin: Ià R 
Polymyxin B: Rà I 
S. aureus    Erythromycin: Ià R 
Polymyxin B: Ià R 
K. pneumoniae Bacitracin Rà I 
Erythromycin: Rà I 
Vancomycin: Rà S 
A. baumannii Bacitracin I à S 
Polymyxin B  I à S 
Vancomycin  Rà I 
P. aeruginosa  Chloramphenicol  I à S 
Polymyxin B  I à S 
E. aerogenes  Polymyxin B  I à S 
Bacitracin  Rà I 
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ESKAPE bacteria after post application treatment as seen in the Live vs. Dead Assay.  
All in all, the burden of the antibiotic resistance ESKAPE pathogens continue to 
increase. Therefore, there is a demand for new antimicrobial medications and natural 
remedies that can potentially circumvent the threat MDR organisms present to our global 
health(Antibiotic 2017; Shin et al. 2018). Previous treatment plans that were considered 
the gold standard of care are no longer effective due to resistance.  However, natural 
remedies and techniques to treat infections are promising, as shown in this study utilizing 
EGCG-S and in aforementioned studies. With research advancements, the development 
of new natural preservatives, replacing antibiotics in our food and cattle, and using 
polyphenols and plant extracts to treat MDR organisms we can potentially combat 
antibiotic resistance.  
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Future Studies 
 
• Monitor combination treatment (antibiotics & EGCG-S) on growth, viability and 
biofilm formation. 
• Utilize the cell sorter to evaluate the population dynamics of bacteria in different 
treatment conditions.  
• Conduct a molecular study of mechanisms of antibiotics & EGCG-S synergy.  
• Utilize primers discussed above to test our isolates for specific antibiotic 
resistance genes to better understand their response to antibiotics and if EGCG-S 
is able to disrupt encoded resistance.  
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